At Enigma Biomedical group, we’re focused on molecular imaging and medicine. We’re on a mission to progress developmental studies in brain health and accelerate them by offering an array of services, so that they’re able to impact the world on a vast, global scale.
From vaccine development to the revolution of genomics, we’re here to set a new standard of excellence.
Just last month, Enigma Biomedical Group announced an exciting collaboration with Invicro.
You may have heard of this company before; they’re the leading provider of imaging services and software in translational drug discovery and development. It’s all very exciting, and a step forward in brain health analysis.
Consistent with our vision, they’ll be focusing on the enhancement of Invicro’s Amyloid and Tau platforms. Together, Enigma Biomedical Group and Invicro will be working on multiple projects focused on neurodegeneration paired with a streamlined approach,
“We are extremely impressed by the Enigma portfolio and look forward to a great research partnership in the coming years” stated Dr. Jack Hoppin, Co-Founder and CEO of Invicro.
This partnership means many things, notable ones being broadening our access to the scientific public through biomarkers imaging and breakthrough algorithms and accelerating the neuro imaging clinical trials. This will support all of the informatics available to the medical community (like the pharmaceutical industry and our academic partners).
“This is an important step in accelerating critical biomarker research projects globally and supporting our pharmaceutical partners efforts to combat neurodegenerative disease.” States Lee-Anne Gibbs, President of Enigma Biomedical Group, “collaborating with Invicro’s IQ technology platform allows Enigma and our partners Cerveau and Meilleur, to continue to execute the collective strategy of providing biomarkers to industry and academics to accelerate research in the field of Neurodegenerative disease.”
Enigma is looking forward to this partnership and many more that will align with their mission and broaden access to novel research.